Secukinumab and TNF-α inhibitors' effect on the humoral response to BNT162b2 mRNA vaccine in spondyloarthritis patients compared to immunocompetent controls
Description
CONCLUSION: SEC did not interfere with the immunogenic response to BNT162b2 vaccine in patients with SpA; however, TNFi was associated with lower S1/S2-antibody titers, faster decline, and higher rate of breakthrough infections.
